AACR: Pembrolizumab Beneficial for Advanced Small Cell Lung Cancer

Antitumor activity promising; objective response rate 19.3 percent for patients with incurable, advanced SCLC
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pulmonology, Conference News, Source Type: news